All filters
Slidesets
Current and Future Treatment of CMV- Robin Avery, MD
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017
Slidesets
O_1: Single- and multiple-ascending doses (SAD/MAD) and food effect of orally administered JNJ-64155806 in healthy volunteers- Thomas Kakuda, PharmD
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017
Slidesets
O_2: Effects of cobicistat on tenofovir durability: is it time to rethink at TAF trials?- Dario Cattaneo, PharmD, PhD
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017
Slidesets
O_4: Evaluation of the Drug-Drug Interaction Potential between Cobicistat-Boosted Protease Inhibitors and Statins - Dr Joseph Custodio
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017
Slidesets
O_5: Confirmation of the drug-drug interaction (DDI) potential between cobicistat-boosted antiretroviral regimens and hormonal contraceptives- Dr Sophia Majeed
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017
Slidesets
O_3: Pharmacokinetics of darunavir/cobicistat and etravirine alone and coadministered in HIV-infected patients- José Moltó, MD, PhD
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017
Slidesets
O_6: Darunavir concentrations in CSF of HIV-infected individuals when boosted with cobicistat versus ritonavir- Catia Marzolini, PharmD, PhD
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017
Slidesets
Current Challenges in Pediatric Drug Development- Robert Ward, MD, FAAP, FCP
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017
Slidesets
Clinical Aspects of Pediatric Treatment- Tim Cressey, PhD
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017
Slidesets
O_8: Relationship between dolutegravir plasma exposure, quality of sleep and its functional outcome in patients living with HIV over the age of 60 years.- Marta Boffito, MD, PhD, FRCP
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017
Slidesets
O_7: A Comparison of the Pharmacokinetics of Dolutegravir during Pregnancy and Postpartum- Dr Pauline Bollen
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017
Slidesets
O_11: HIV-1-infected Males and Females under Less-Drug Regimens Achieve Antiretroviral Levels above the Inhibitory Concentration in the Genital Tract.- Sandrine Lefeuvre
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017
Slidesets
HBV therapy & Approaches to Cure- Jordan Feld, MD, MPH
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017
Slidesets
FDA perspective- Kellie Reynolds, PharmD
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017
Slidesets
O_13: CYP3A induction data can predict other P450 and drug transporter DDI liability: An example of carbamazepine and rifabutin with sofosbuvir and P-gp- Brian Kirby, MD
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017
Slidesets
O_12: Examining the Basis of Drug-Drug Interaction Labeling Recommendations for Antiviral Approvals from 1998 to 2015- Tyler Shugg, PharmD, PhD
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017
Slidesets
DDI’s in Aging HIV infected Patients- Alice Pau, PharmD
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017
Slidesets
Long Acting Antivirals: Advanced drug delivery- Mark Milad, PharmD
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017
Slidesets
DDI’s in Aging HCV infected Patients- Elise Smolders, MSc
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017
Slidesets
O_14: Pharmacokinetics of Co-encapsulated Truvada® with Ingestible Sensor to Assess Adherence- Nathan Hanan
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017
Slidesets
O_16: A mathematical model that predicts virological failure and elucidates the impact of lymph node drug penetration- Steven Sanche
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017
Slidesets
O_15: Identification of long-acting NRTI candidates through in silico modelling- Marco Siccardi, PhD
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017
Slidesets
O_17: Early Safety, Tolerability, and Pharmacokinetic Profile of GSK2838232, a Novel 2nd Generation HIV Maturation Inhibitor, as Assessed in Healthy Subjects- Mark Johnson, MD
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017